These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11420602)

  • 41. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells.
    Lucci A; Han TY; Liu YY; Giuliano AE; Cabot MC
    Cancer; 1999 Jul; 86(2):300-11. PubMed ID: 10421266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
    Modok S; Mellor HR; Callaghan R
    Curr Opin Pharmacol; 2006 Aug; 6(4):350-4. PubMed ID: 16690355
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Click reactions with functional sphingolipids.
    Fink J; Seibel J
    Biol Chem; 2018 Sep; 399(10):1157-1168. PubMed ID: 29908120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glucose availability and glycolytic metabolism dictate glycosphingolipid levels.
    Stathem M; Marimuthu S; O'Neal J; Rathmell JC; Chesney JA; Beverly LJ; Siskind LJ
    J Cell Biochem; 2015 Jan; 116(1):67-80. PubMed ID: 25145677
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
    Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
    Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells.
    Klappe K; Hinrichs JW; Kroesen BJ; Sietsma H; Kok JW
    Int J Cancer; 2004 Jul; 110(4):511-22. PubMed ID: 15122583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes.
    Vergote J; Moretti JL; de Vries EG; Garnier-Suillerot A
    Eur J Biochem; 1998 Feb; 252(1):140-6. PubMed ID: 9523723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular mechanisms of drug resistance and its reversal in cancer.
    Kartal-Yandim M; Adan-Gokbulut A; Baran Y
    Crit Rev Biotechnol; 2016 Aug; 36(4):716-26. PubMed ID: 25757878
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.
    Morad SA; Cabot MC
    Biochim Biophys Acta; 2015 Sep; 1851(9):1134-45. PubMed ID: 25964209
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
    Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
    Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come?
    Radin NS
    Eur J Biochem; 2001 Jan; 268(2):193-204. PubMed ID: 11168352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ceramide: from embryos to tumors.
    Savtchouk IA; Mattie FJ; Ollis AA
    Sci STKE; 2007 Jul; 2007(394):jc1. PubMed ID: 17622645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sphingolipid-binding proteins.
    Snook CF; Jones JA; Hannun YA
    Biochim Biophys Acta; 2006 Aug; 1761(8):927-46. PubMed ID: 16901751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells.
    Prinetti A; Millimaggi D; D'Ascenzo S; Clarkson M; Bettiga A; Chigorno V; Sonnino S; Pavan A; Dolo V
    Biochem J; 2006 Apr; 395(2):311-8. PubMed ID: 16356169
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution.
    Breuninger LM; Paul S; Gaughan K; Miki T; Chan A; Aaronson SA; Kruh GD
    Cancer Res; 1995 Nov; 55(22):5342-7. PubMed ID: 7585598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.
    Mohammad IS; He W; Yin L
    Biomed Pharmacother; 2018 Apr; 100():335-348. PubMed ID: 29453043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sphingolipid synthetic pathways are major regulators of lipid homeostasis.
    Worgall TS
    Adv Exp Med Biol; 2011; 721():139-48. PubMed ID: 21910087
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ceramide transfer protein and cancer.
    Scheffer L; Raghavendra PR; Ma J; Acharya JK
    Anticancer Agents Med Chem; 2011 Nov; 11(9):904-10. PubMed ID: 21707482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes.
    Bellini L; Campana M; Mahfouz R; Carlier A; Véret J; Magnan C; Hajduch E; Le Stunff H
    Expert Opin Ther Targets; 2015; 19(8):1037-50. PubMed ID: 25814122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.